Floatz logo

DOXORUBICIN

Primary Peritoneal Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.Small moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
89/ 100

Competitive context

148 Active assets in the Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
NOGITECAN
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB
FILGRASTIM
Roswell Park Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

DOXORUBICIN is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →